Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 42.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,067 shares of the company’s stock after buying an additional 65,826 shares during the quarter. Geode Capital Management LLC owned approximately 0.87% of Tempest Therapeutics worth $308,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TPST. Fullcircle Wealth LLC purchased a new stake in shares of Tempest Therapeutics during the 3rd quarter worth about $87,000. Empower Advisory Group LLC acquired a new position in Tempest Therapeutics during the 3rd quarter worth approximately $49,000. Dimensional Fund Advisors LP acquired a new position in shares of Tempest Therapeutics in the 2nd quarter valued at approximately $55,000. Finally, XTX Topco Ltd acquired a new position in shares of Tempest Therapeutics in the 3rd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TPST shares. Piper Sandler dropped their price target on Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a research note on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 target price on shares of Tempest Therapeutics in a research note on Wednesday, November 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $20.00.

Tempest Therapeutics Stock Down 2.8 %

Shares of NASDAQ TPST opened at $0.92 on Tuesday. Tempest Therapeutics, Inc. has a 12 month low of $0.70 and a 12 month high of $6.00. The company has a market cap of $40.26 million, a price-to-earnings ratio of -0.60 and a beta of -1.69. The business has a fifty day simple moving average of $0.90 and a 200-day simple moving average of $1.27.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.04). As a group, sell-side analysts expect that Tempest Therapeutics, Inc. will post -1.39 EPS for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.